Evonetix raises £20m in a Series B round led by Foresite Capital to scale DNA synthesis chips.
The oversubscribed round included backing from Molten Ventures, Morningside, DCVC, Cambridge Consultants, Civilization Ventures and Providence.
Share allotment filed at Companies House
Evonetix develops semiconductor technology applied to DNA synthesis, offering a benchtop platform for accurate gene assembly. The firm uses a silicon chip to control synthesis across thousands of reaction sites.
Evonetix has secured £20m in a Series B extension round led by Foresite Capital. The financing included participation from several existing backers as the firm prepares to scale its semiconductor chip technology commercially. The capital will support the development of benchtop gene synthesis instrumentation and the expansion of binary assembly capabilities.
From the founder
"This substantial investment round demonstrates continued confidence in the progress of our technical development and its potential to revolutionise the accessibility of gene synthesis. Evonetix is in a very exciting phase, having recently opened our early access program. This investment will support us as we execute on our commercial strategy to put benchtop gene synthesis in the hands of users."
Colin McCracken
Chief Executive Officer at Evonetix
Investor perspective
"Molten has been a big supporter of Evonetix from the early days. We are delighted with the huge progress the company has made towards revolutionising the gene synthesis process and look forward to continuing our partnership."
Nelly Markova
Principal, Molten
Use of funds
- 01Continue product development
Investors
Foresite Capital
Nelly Markova
Molten
Morningside
DCVC
Cambridge Consultants
Civilization Ventures
Providence